Entheon Biomedical Corp.
ENTBF
$0.00
$0.000.00%
OTC PK
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.47% | -6.68% | 2.32% | -1.96% | -7.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.47% | -6.68% | 2.32% | -1.96% | -7.50% |
| Operating Income | 29.47% | 6.68% | -2.32% | 1.96% | -35.29% |
| Income Before Tax | 27.90% | 1.42% | -7.96% | -2.76% | -34.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.90% | 1.42% | -7.96% | -2.76% | -34.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.90% | 1.42% | -7.96% | -2.76% | -34.68% |
| EBIT | 29.47% | 6.68% | -2.32% | 1.96% | -35.29% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 57.62% | 42.77% | 36.04% | 39.75% | 13.71% |
| Normalized Basic EPS | 57.98% | 43.30% | 39.73% | 41.86% | 15.70% |
| EPS Diluted | 57.62% | 42.77% | 36.04% | 43.95% | 26.16% |
| Normalized Diluted EPS | 57.98% | 43.30% | 39.73% | 41.86% | 15.70% |
| Average Basic Shares Outstanding | 67.81% | 73.25% | 73.57% | 74.05% | 56.78% |
| Average Diluted Shares Outstanding | 67.81% | 73.25% | 73.57% | 74.05% | 56.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |